Company Filing History:
Years Active: 1992
Title: Max H Schreier: Innovator in Monoclonal Antibodies
Introduction
Max H Schreier is a prominent inventor based in Basel, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 2 patents, his work has advanced the understanding and application of cyclosporins in medical science.
Latest Patents
One of Schreier's latest patents focuses on monoclonal antibodies to cyclosporins. This innovation involves the production of novel monoclonal antibodies capable of distinguishing between various cyclosporins and their metabolites. The patent details the use of cyclosporins with activated coupling groups, which are essential for creating new antigenic conjugates and hybridoma cell lines. These advancements have implications for the production of antibodies and antisera, as well as the development of assay kits that utilize these novel components.
Career Highlights
Max H Schreier is associated with Sandoz GmbH, a leading company in the pharmaceutical industry. His work at Sandoz has allowed him to collaborate with other experts in the field, enhancing the impact of his research. His contributions have not only advanced scientific knowledge but have also paved the way for new therapeutic applications.
Collaborations
Throughout his career, Schreier has worked alongside notable colleagues such as Joachim Rosenthaler and Roland M Wenger. These collaborations have fostered a productive environment for innovation and have led to significant advancements in their shared field of research.
Conclusion
Max H Schreier's work in the development of monoclonal antibodies represents a significant advancement in biotechnology. His innovative patents and collaborations continue to influence the field, showcasing the importance of research and development in medical science.